NCT05619783Phase 3Completed

Extension Study Evaluating The Safety And Tolerability of AMX0035

Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-10-16Actual
Enrollment · participants352Actual
Source updated2025-01-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview